ITM and ILL Extend Collaboration on the Manufacturing and Supply of Medical Lutetium-177 Radioisotope
Garching / Munich, Germany, and Grenoble, France, June 16, 2025 – ITM Isotope Technologies Munich SE (ITM) and the Institut Laue-Langevin (ILL), today announced an extension of their collaboration for medical radioisotope production, originally established in 2009. Under the terms of the renewed agreement, ITM will receive priority access to half of the available neutron irradiation capacity at ILL's High-Flux Reactor, its neutron irradiation facility, for the production of non-carrier-added Lutetium-177 (n.c.a. Lu-177), a critical medical radioisotope used for radiopharmaceutical therapies for cancer treatment and diagnosis. As the globally leading manufacturer of n.c.a. Lu-177, ITM is committed to maintaining and expanding its robust manufacturing and production capabilities to meet the growing demand for this vital medical radioisotope.
'ITM and ILL's longstanding partnership began in 2009, when the radiopharmaceutical industry was still in its infancy,' commented Dr. Andrew Cavey, CEO of ITM. 'Our priority access to ILL's renowned high-flux irradiation services is incredibly important as the demand for n.c.a. Lutetium-177 grows and as our radiopharmaceutical pipeline evolves.'
The high neutron flux of ILL's reactor provides ITM with a high yield of Lu-177, and allows for a particularly sustainable production of the medical radioisotope by minimizing use of the scarce precursor raw material, Ytterbium-176 (Yb-176). Providing radioisotopes to ITM plays a significant role in enabling geographic and industrial return from ILL to its funding countries, fostering innovation and supporting advancements in radiopharmaceutical research and production.
Dr. Ken Andersen, Director of the Institut Laue-Langevin added, 'ILL operates the world-leading neutron source for research by neutron scattering and in nuclear and particle physics. Moreover, ILL's reactor provides irradiation positions at exceptionally high neutron flux that are exploited both for fundamental research and the production of radionuclides for medical applications. ILL is proud of the longstanding collaboration with ITM, regularly performing irradiations of Ytterbium-176 targets for ITM over the last 15 years, and looks forward to an even closer partnership in the coming years.'About Radiopharmaceutical Therapy (RPT)Radiopharmaceutical Therapy (RPT) is an emerging class of cancer therapeutics, which seeks to deliver radiation directly to the tumor while minimizing radiation exposure to healthy tissue. Targeted radiopharmaceuticals are created by linking a therapeutic radioisotope such as Lutetium-177 or Actinium-225 to a targeting molecule (e.g., peptide, antibody, small molecule) that can precisely recognize tumor cells and bind to tumor-specific characteristics, such as receptors on the tumor cell surface. As a result, the radioisotope accumulates at the tumor site and decays, releasing a small amount of ionizing radiation, with the goal of destroying tumor tissue. The precise localization enables targeted treatment with potentially minimal impact to healthy surrounding tissue.
About ITM Isotope Technologies Munich SEITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including two phase III studies, combining the company's high-quality radioisotopes with a range of targeting molecules. By leveraging our nearly two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life. www.itm-radiopharma.comAbout the ILL, Institut Laue-LangevinThe ILL is the world-leading facility in neutron science and technology. Delivering the most intense neutron beams in the world to its unparalleled suite of 43 state-of-the-art neutron scattering instruments, the ILL offers a unique tool for probing the heart of matter. Every year, around 1500 international researchers visit the ILL to carry out over 1000 cutting-edge experiments in a variety of disciplines, including physics, chemistry, biology, and material science and engineering. Besides its impact in scientific research and education excellence, the ILL helps drive innovation in the fields of health, energy, the environment and quantum materials. The ILL is engaged in the production of radioisotopes for medical applications since more than 15 years now. A major European project, the ILL was founded in Grenoble in 1967 by France and Germany, joined a few years later by the UK. Today, 13 countries fund the facility for their research communities.ITM ContactCorporate CommunicationsKathleen Noonan / Julia WestermeirPhone: +49 89 329 8986 1500Email: communications@itm-radiopharma.comInvestor RelationsBen OrzelekPhone: +49 89 329 8986 1009Email: investors@itm-radiopharma.comILL ContactRadionuclide ProductionUlli Köster Phone: (+33) (0)4 76 20 71 54Email: koester@ill.frCommunicationsCatarina Espirito SantoPhone: (+33) (0)4 76 20 71 07Email: communication@ill.fr
Attachment
20250616_ITM and ILL Extend Collaboration on the Manufacturing and Supply of Medical Lutetium-177 Radioisotope
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Cannabis Linked to 2x Risk of Heart Disease Death, Scientists Discover
New research suggests that cannabis use is linked to twice the risk of death from cardiovascular disease, and is also associated with increased risk of other major adverse cardiovascular events (MACE). Cannabis is being legalized in more and more places worldwide, increasing medicinal and recreational use – but it may warrant closer monitoring by health professionals. The researchers here, led by a team from the University of Toulouse in France, wanted to look more closely at potential health risks that had previously been flagged. They looked at 24 previous studies published between 2016 and 2023, involving around 200 million people. Overall, the increased risk linked to cannabis use was 29 percent for acute coronary syndrome (reduced blood flow to the heart), 20 percent for strokes, and 100 percent for cardiovascular disease mortality. "The findings reveal positive associations between cannabis use and MACE," write the researchers in their published paper. "These findings should encourage investigating cannabis use in all patients presenting with serious cardiovascular disorders." There are some limitations worth bearing in mind here. The studies included in the research differed in terms of how they defined cannabis use, relied on self-reporting, and didn't measure use of the drug over time. That makes them less statistically robust. The research also notes a high risk of bias in the majority of studies investigated, due to the way they were structured. And it's important to say the research doesn't show direct cause and effect, only an association. It's possible that other factors not considered here are driving both cannabis use and heart health issues in certain groups of people. Nevertheless, the large number of people surveyed on their real-world use of cannabis counts in the study's favor. It also has more recent data than many other studies, and we know that cannabis use and composition is changing over time. That's enough to warrant deeper investigation into the possible health risks. "Legalizing the drug and expanding its medical use worldwide have likely contributed to profound changes in the general perception of cannabis and to the overall rise in cannabis consumption," write the researchers. "Consequently, users' profiles and consumption habits profoundly differ from those in the 2010s, especially as cannabis products show an increasing trend in potency, with rising concentrations of delta-9-tetrahydrocannabinol (THC)." Further research is absolutely needed here, not least to determine whether the chemicals and compounds in cannabis – of which there are hundreds – could be leading to these health risks, and how taking cannabis in different forms, such as inhalables or edibles, might have an influence. Previous studies have already shown how the drug can increase the risk of cancer, and significantly alter our DNA, for example. Cannabis could also trigger psychosis through the impact it has on the brain. The new study is accompanied by an editorial written by epidemiologists Stanton Glanz and Lynn Silver, from the University of California San Francisco. In it, Glanz and Silver argue that as cannabis use rises, more should be done to educate people about the risks – as has been done with cigarettes. "Specifically, cannabis should be treated like tobacco: not criminalized but discouraged, with protection of bystanders from secondhand exposure," they write. The research has been published in the journal Heart. 5 Daily Habits Could Be Causing Your Liver Serious Harm FDA-Approved Sleeping Pill Slows Alzheimer's Tangles in Pre-Clinical Trial Risk of Sleep Breathing Disorder Set to Rise 45% by End of Century
Yahoo
3 hours ago
- Yahoo
Company unveils device inspired by cotton candy machines to solve pressing household waste issue: 'Drama that should be avoided at all costs'
While plastic recycling has been around for decades, the technology has not always been accessible to communities in remote locations. This has led to the prevalence of plastic pollution and the emergence of microplastics in the environment. However, as Interplas Insights reported, one Paris-based company has created a compact machine that may provide a convenient and efficient solution to plastic waste. Founded in 2012, The Polyfloss Factory has developed a technology that is able to transform plastic waste into soft, versatile fibers, which it said is inspired by cotton candy machines. With the introduction of their mini machines, they offer local recycling facilities in areas where large-scale industrial recycling is not possible, particularly in developing countries and remote locations. Audrey Gaulard, co-founder and COO of The Polyfloss Factory, emphasized the importance of the company's technology and the impact that it may have on tackling growing concerns about microplastics, which have been linked to a range of human health issues. "Microplastics is a drama that should be avoided at all costs," Gaulard told Interplas Insights. "The Polyfloss create long fibers, so they are not creating microplastics as such. Unlike short fibres that you can find in recycled pullovers for example, polyfloss is not as nimble as those." According to The Polyfloss Factory website, these fibers can be used in various applications, including textiles, packaging, insulation, and even construction. Once produced, the fibers are able to be "threaded, woven, knitted, or even felted with felting needles techniques." Not only does this process give users the ability to use the fibers in many different ways, but it also helps cut down on the increasing amount of plastic pollution. "We can't rely solely on current waste management systems," Emile De Visscher, co-founder and CEO of The Polyfloss Factory, told Interplas Insights. "We need local, creative circular economies." As a report from the International Union for Conservation of Nature observed, over 460 million metric tons of plastic is produced around the globe each year. This results in around 20 million metric tons of plastic waste ending up in the environment. What's the biggest obstacle stopping your organization from using solar panels? They're too expensive Don't know where to start They're an eyesore We already use solar panels Click your choice to see results and speak your mind. Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet.
Yahoo
5 hours ago
- Yahoo
Diary from Cannes: AI's impact on business, a stalled economy, and Disney's succession
As a journalist, you never quite know what you'll learn at a conference where top executives are floating around. Someone like me — the interested observer — is always paying attention to varying things on the ground: the watches execs are wearing (they say a lot), who's wearing health trackers (also says a lot), who's huddled in a corner talking shop, and what their body language is. And of course, what people are actually telling me. To that end, I return from a week at the Cannes Lions advertising and media industry conference. The best way I can describe this event is it's as if the World Economic Forum bought LiveNation and created a rebellious sister conference. By subscribing, you are agreeing to Yahoo's Terms and Privacy Policy This year, I saw and heard a bit of everything, including from NFL great Chad Johnson, who shared he lived in the Cincinnati Bengals' training facility for the first two years of his career to save money. I didn't expect to hear that. I also didn't expect to hear this from DJ Diplo: "I have sold my music catalog a few times. You can always sell and build more. I did a 75% sale like five years ago, and I already built another catalog that I want to maybe move again, because sometimes I'd rather have capital to invest in other things." Where is he putting that fresh capital to work? He said medical devices, fintech companies, and real estate. Suffice to say, this coming week I plan to weave more observations into my new show at Yahoo Finance called Opening Bid. I will debut the show live Monday through Friday from 9:30 a.m. to 10 a.m. ET in a fast-paced format. Excited to bring you the fire (i.e., stock analysis and big interviews). You can watch here or on our app, all major streaming platforms, and DirecTV. Have something you want me to discuss on Monday? Drop me a line today on X @BrianSozzi. In the meantime, here's a roundup of things that stood out to me from my chats on the beach. "Nothing is ever really off the table, and really, the mindset of what's possible is always encouraged." "What I would say there is what's important to us is that we are able to protect our users' privacy, their deletion rights, like we have policies that ensure that when users take down a post, the post is taken down. And so it's really important, and as we've said in our terms of service, that we have a conversation with folks who have access to our data because that's a commitment that we have in terms of our policies, and it's also to know how Reddit data is used." "If I were going to advise the new CEO of Disney, I would say stay close to Bob Iger for the first six months. Really take that apprenticeship to heart because Bob is an amazing CEO — very few like him. If you can just be at his side and look at the whole company ... but get close to Bob, sit by his side, and just learn how he does things." "Look, I'm a consummate optimist, and no matter how difficult it is out there, there are holidays that come. People want to be celebrating with their families. Santa comes every year." "I think it's harder than most people realize. And the interesting thing is, for the past five to 10 years, we have been putting them together — linear TV content creates the streaming content. Now all of that has changed." "I think people are being very intentional where they spend money. It's cyclical, right? So it happens, you know, things get better, and that comes back. What we have seen is that it happens every single time the same way." Brian Sozzi is Yahoo Finance's Executive Editor and a member of Yahoo Finance's editorial leadership team. Follow Sozzi on X @BrianSozzi, Instagram, and LinkedIn. Tips on stories? Email Sign in to access your portfolio
